Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage

Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical trials as a glucose-lowering drug, but its role and mechanism on renal fibrosis remain unclear. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jianhua, Huang, Hao, Zhang, Yan, Lv, Xin, Cheng, Jiawei, Zou, Si Jue, Han, Yuanyuan, Wang, Songkai, Gong, Li, Peng, Zhangzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028454/
https://www.ncbi.nlm.nih.gov/pubmed/36959860
http://dx.doi.org/10.3389/fphar.2023.1095487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028454/
https://www.ncbi.nlm.nih.gov/pubmed/36959860
http://dx.doi.org/10.3389/fphar.2023.1095487

Ejemplares similares